H1 2025 saw revenue and EBITDA losses due to operational suspensions, civil unrest, and weak demand, but recent rights issue and asset sales have improved liquidity. Kagem and MRM production are recovering, with new plant ramp-up expected to boost output and efficiency.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.